Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 39-48

  Liu, Haiyan ^a   Enyeart, Judith A ^a   Enyeart, John J ^a   Ohio, ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANANDAMIDE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CANNABINOID; DIHYDROPYRIDINE; FLUNARIZINE; NIFEDIPINE; NIGULDIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.4; TREK 1 POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR SYSTEM; CELL MEMBRANE POTENTIAL; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CONTROLLED STUDY; COW; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZONA FASCICULATA;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CATTLE; CELLS, CULTURED; DIHYDROPYRIDINES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; ZONA FASCICULATA;

EID: 34548832288     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125245     Document Type: Article

References (42)

1. TREK in cardiomyocytes. J Biol Chem 275:39110-39116.
2. + channel involved in polymodal pain perception. EMBO J 25:2368-2376.
3. Bockenhauer D, Zilberberg N, and Goldstein SA (2001) KCNK2: reversible conversion of a hippocampal potassium leak into a voltage-dependent channel. Nat Neurosci 4:486-491.
4. Brooks SP and Storey KB (1992) Bound and determined: a computer program for making buffers of defined ion concentrations. Anal Biochem 201:119-126.
5. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, and Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033-7040.
6. Cohen C, Perrault G, and Sanger DJ (1997) Assessment of the antidepressant-like effects of L-type voltage-dependent channel modulators. Behav Pharmacol 8:629-638.
7. Czyrak A, Mogilnicka E, and Maj J (1989) Dihydropyridine calcium channel antagonists as antidepressant drugs in mice and rats. Neuropharmacology 28:229-233.
8. 2+- and ATP hydrolysis-dependent mechanisms. J Biol Chem 280:30814-30828.
9. + current in adrenal cortical cells through nonhydrolytic binding. J Gen Physiol 110:679-692.
10. 2+ channels are required for ACTH-stimulated cortisol synthesis by bovine adrenal zona fasciculata cells. Mol Endocrinol 7:1031-1040.
11. + current in adrenocortical cells by an A-kinase-independent mechanism requiring ATP hydrolysis. J Gen Physiol 108:251-264.
12. + channel in adrenocortical cells is TREK-1. J Biol Chem 277:49186-49199.
13. + channels. Am J Physiol Endocrinol Metab 282:E1255-E1266.
14. Fleckenstein A, Frey M, Zorn J and Fleckenstein-Grün G (1989) Amlodipine, a new 1,4-dihydropyridine calcium antagonist with a particularly strong antihypertensive profile. Am J Cardiol 64:21I-34I.
15. Franks NP and Honoré E (2004) The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci 25:601-608.
16. Gomora JC and Enyeart JJ (1999a) Dual pharmacological properties of a cyclic AMP-sensitive potassium channel. J Pharmacol Exp Ther 290:266-275.
17. + channels in adrenal cells. Mol Pharmacol 56:1192-1197.
18. 2+ channels in cortisol-secreting cells. J Pharmacol Exp Ther 292:96-103.
19. + channels TREK-1 and TASK-3 are differentially modulated by copper and zinc. Mol Pharmacol 66:530-537.
20. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85-100.
21. Harinath S and Sikdar SK (2005) Inhibition of human TREK-1 channels by caffeine and theophylline. Epilepsy Res 64:127-135.
22. 2+ channels. Jpn J Pharmacol 85:339-350.
23. Hervieu GJ, Cluderay JE, Gray CW, Green PJ, Ranson JL, Randall AD, and Meadows HJ (2001) Distribution and expression of TREK-1, a two-pore-domain potassium channel, in the adult rat CNS. Neuroscience 103:899-919.
24. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, et al. (2006) Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9:1134-1141.
25. Hoffman BB (2005) Therapy of hypertension, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton L, Lazo J, and Parker K eds) pp 845-868, McGraw-Hill Professional, New York.
26. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, and Mathie A (2005) Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 144:821-829.
27. Lesage F and Lazdunski M (2000) Molecular and functional properties of two-poredomain potassium channels. Am J Physiol Renal Physiol 279:F793-F801.
28. Li XT, Dyachenko V, Zuzarte M, Putzke C, Preisig-Müller R, Isenberg G, and Daut J (2006) The stretch-activated potassium channel TREK-1 in rat cardiac ventricular muscle. Cardiovasc Res 69:86-97.
29. Maingret F, Patel AJ, Lazdunski M, and Honoré E (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J 20:47-54.
30. Mason RP, Campbell SF, Wang SD, and Herbette LG (1989) Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 36:634-640.
31. + channels TREK-1 and TRAAK. Brain Res 892:94-101.
32. Michel T (2005) Treatment of myocardial ischemia, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton L, Lazo J, and Parker K eds) pp 823-844, McGraw-Hill Professional, New York.
33. + current inhibited by ACTH and angiotensin II in adrenal cortical cells. J Biol Chem 268:8640-8644.
34. + current. J Gen Physiol 102:239-255.
35. 2+ currents in atrial myocytes. Pflugers Archiv 420:410-412.
36. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, and Snutch TP (2002) Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 22:396-403.
37. 2+ channel is the predominant subtype expressed in bovine and rat zona glomerulosa. Am J Physiol Cell Physiol 280:C265-C272.
38. 2+ channels in neuroblastomaglioma hybrid cells. Eur J Pharmacol 342:339-345.
39. Talley EM, Solorzano G, Lei Q, Kim D, and Bayliss DA (2001) CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 21:7491-7505.
40. Tan JHC, Liu W, and Saint DA (2002) Trek-like potassium channels in rat cardiac ventricular myocytes are activated by intracellular ATP. J Membr Biol 185:201-207.
41. Terrenoire C, Lauritzen I, Lesage F, Romey G, and Lazdunski M (2001) A TREK-1-like potassium channel in atrial cells inhibited by beta-adrenergic stimulation and activated by volatile anesthetics. Circ Res 89:336-342.
42. Thümmler S, Duprat F, and Lazdunski M (2007) Antipsychotics inhibit TREK but not TRAAK channels. Biochem Biophys Res Commun 354:284-289.